Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note issued on Wednesday. The firm set a “sell” rating on the stock.

Oragenics Price Performance

Shares of OGEN stock opened at $0.27 on Wednesday. The stock has a market cap of $3.30 million, a P/E ratio of -0.04 and a beta of 0.49. The company has a fifty day moving average price of $0.37 and a two-hundred day moving average price of $1.01. Oragenics has a one year low of $0.25 and a one year high of $7.74.

Hedge Funds Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new stake in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.